CVKD NASDAQ
Cadrenal Therapeutics, Inc. Common Stock
1W: -1.9%
1M: -11.8%
3M: -24.5%
YTD: -29.5%
1Y: -67.0%
3Y: -76.4%
$5.19
+0.02 (+0.39%)
Weekly Expected Move ±14.4%
$4
$4
$5
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$14.9M
52W Range4.21-15.99
Volume101,401
Avg Volume57,173
Beta1.83
Dividend—
Analyst Ratings
Company Info
CEOQuang X. Pham
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2023-01-20
Websitecadrenal.com
822 A1A North
Ponte Vedra, FL 32082
US
Ponte Vedra, FL 32082
US
904 300 0701
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Latest News
Cadrenal Therapeutics reports Q1 results
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
12 Health Care Stocks Moving In Friday's After-Market Session
Cadrenal Therapeutics GAAP EPS of -$6.64
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Szot Matthew K | S-Sale | 9,933 | $6.97 | 2025-12-29 |
| Golden Lee Scott | A-Award | 5,000 | $8.27 | 2025-12-02 |
| Golden Lee Scott | 0 | — | 2025-11-24 | |
| Szot Matthew K | S-Sale | 1,800 | $13.99 | 2025-10-27 |
| Pham Quang X | S-Sale | 1,315 | $13.99 | 2025-10-27 |